Added to YB: 2024-02-16
Pitch date: 2024-02-15
GILD [bullish]
Gilead Sciences, Inc.
+92.36%
current return
Author Info
No bio for this author
Company Info
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Market Cap
$165.2B
Pitch Price
$67.84
Price Target
128.00 (-2%)
Dividend
2.47%
EV/EBITDA
11.84
P/E
18.10
EV/Sales
5.93
Sector
Biotechnology
Category
turnaround
Gilead Sciences: 2024 Catalysts Should Drive Growth And Change In Sentiment
GILD: Flat since 2015 but bullish on 2024 turnaround - growth via earnings, drug approvals, pipeline, dividends. $4.3B Cymbal deal = long-term liver disease focus. Low 10.47 P/E near trough, 12 qtrs of growth. DCF = safety margin, $128 PT by 2027 w/ 16 P/E on projected EPS. Patience key.
Read full article (5 min)